Estimated Long-Term Survival With Eplerenone

Journal of the American College of Cardiology

Volumn 73, Issue 18, 2019, Pages 2357-2359

  Stienen, Susan ^a   Ferreira, João Pedro ^a   Vincent, John ^a   Busselen, Martijn ^a   Li, Benjamin ^a   McMurray, John J V ^a   Pitt, Bertram ^a   Girerd, Nicolas ^a   Rossignol, Patrick ^a   Zannad, Faiez ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPLERENONE; PLACEBO; MINERALOCORTICOID ANTAGONIST;

ACUTE HEART INFARCTION; AGING; ALL CAUSE MORTALITY; CONFIDENCE INTERVAL; DRUG EFFECT; FOLLOW UP; HAZARD RATIO; HEART DEATH; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; LETTER; LONG TERM SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME; DIAGNOSIS; ETIOLOGY; FEMALE; HEALTH SERVICE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MALE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME;

EPLERENONE; FEMALE; HEALTH SERVICES MISUSE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; TIME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85064922352     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2019.02.043     Document Type: Letter

References (5)

1. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70 (2017), 776–803.
2. Savarese, G., Carrero, J.J., Pitt, B., et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 20 (2018), 1326–1334.
3. Zannad, F., McMurray, J.J., Krum, H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364 (2011), 11–21.
4. Pitt, B., Remme, W., Zannad, F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003), 1309–1321.
5. Dehbi, H.M., Royston, P., Hackshaw, A., Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards. BMJ, 357, 2017, j2250.